GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025

GRI Bio, Inc.

2024-Q3 EPS reported -$4.56

Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.
Cash and cash equivalents $4.7M as of Sep 30, 2024.
Raised $13.9M gross proceeds since start of 2024, extending runway into mid Q1 2025.
Interim data from GRI-0621 Phase 2a biomarker study expected Q1 2025; topline Q2 2025.
Preclinical data presented; Japan patent granted; Australian study authorization received.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.